Cargando…
Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
Dupilumab is a novel anti–IL-4 receptor-α mAb that targets the signaling pathways of IL-4 and IL-13. Thus far, the data about adequate humoral immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients who are taking dupilumab have been limited...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598042/ https://www.ncbi.nlm.nih.gov/pubmed/36313899 http://dx.doi.org/10.1016/j.jacig.2022.08.007 |